Paper40705396
Durvalumab versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial.
Ngoi NYL and 18 others. Clin Cancer Res, 2025. Cited by 9 papers, by iCite.
Cite this record
ConductScience Library. Durvalumab versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial. Papers, record 40705396. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40705396
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Ovarian Neoplasms | Major topic |
| Adenocarcinoma, Clear Cell | Major topic |
| Antibodies, Monoclonal | Major topic |
| Neoplasm Recurrence, Local | Major topic |
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Humans | |
| Female | |
| Middle Aged | |
| Aged | |
| Adult | |
| Aged, 80 and over | |
| Progression-Free Survival |
Source PubMed
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| AstraZeneca (AstraZeneca PLC) | PubMed | |||
| NMRC/MOHIAFCat1/0061/2016 | National Medical Research Council (NMRC) | PubMed | ||
| CSASI21jun-0003 | Indian Institute of Science Education and Research Mohali (IISER) | PubMed | ||
| Pangestu Family Foundation Gynaecological Cancer Research Fund | PubMed |
Source PubMed
References28
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 34322886 | A multi-ethnic analysis of immune-related gene expression signatures in patients with ovarian clear cell carcinoma. | J Pathol | 2021 | https://conductscience.org/library/papers/34322886 | PubMed |
| 2 | 36244829 | A phase II evaluation of temsirolimus with carboplatin and paclitaxel followed by temsirolimus consolidation in clear cell ovarian cancer: An NRG oncology trial. | Gynecol Oncol | 2022 | https://conductscience.org/library/papers/36244829 | PubMed |
| 3 | 39710508 | Phase II randomized study of dostarlimab alone or with bevacizumab versus non-platinum chemotherapy in recurrent gynecological clear cell carcinoma (DOVE/APGOT-OV7/ENGOT-ov80). | J Gynecol Oncol | 2025 | https://conductscience.org/library/papers/39710508 | PubMed |
| 4 | 35264433 | PI3K activation allows immune evasion by promoting an inhibitory myeloid tumor microenvironment. | J Immunother Cancer | 2022 | https://conductscience.org/library/papers/35264433 | PubMed |
| 5 | 36095166 | The Tumor Microenvironment of Clear-Cell Ovarian Cancer. | Cancer Immunol Res | 2022 | https://conductscience.org/library/papers/36095166 | PubMed |
| 6 | 10861437 | Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. | Cancer | 2000 | https://conductscience.org/library/papers/10861437 | PubMed |
| 7 | 30824583 | Glioblastoma-Derived IL6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth. | Clin Cancer Res | 2019 | https://conductscience.org/library/papers/30824583 | PubMed |
| 8 | 21343371 | IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. | Clin Cancer Res | 2011 | https://conductscience.org/library/papers/21343371 | PubMed |
| 9 | 29739622 | Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001). | Gynecol Oncol | 2018 | https://conductscience.org/library/papers/29739622 | PubMed |
| 10 | 21640372 | Prognosis of ovarian clear cell carcinoma compared to other histological subtypes: a meta-analysis. | Gynecol Oncol | 2011 | https://conductscience.org/library/papers/21640372 | PubMed |
| 11 | 28344892 | Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression. | Oncoimmunology | 2017 | https://conductscience.org/library/papers/28344892 | PubMed |
| 12 | 28266140 | Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma. | Cancer Sci | 2017 | https://conductscience.org/library/papers/28266140 | PubMed |
| 13 | 35816189 | Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes. | Clin Cancer Res | 2022 | https://conductscience.org/library/papers/35816189 | PubMed |
| 14 | 26813747 | Mismatch Repair Protein Expression in Clear Cell Carcinoma of the Ovary: Incidence and Morphologic Associations in 109 Cases. | Am J Surg Pathol | 2016 | https://conductscience.org/library/papers/26813747 | PubMed |
| 15 | 31046082 | Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. | Ann Oncol | 2019 | https://conductscience.org/library/papers/31046082 | PubMed |
| 16 | 34247767 | Clear cell carcinoma of the ovary: Epidemiology, pathological and biological features, treatment options and clinical outcomes. | Gynecol Oncol | 2021 | https://conductscience.org/library/papers/34247767 | PubMed |
| 17 | 34064019 | Estimating Relative Risk When Observing Zero Events-Frequentist Inference and Bayesian Credibility Intervals. | Int J Environ Res Public Health | 2021 | https://conductscience.org/library/papers/34064019 | PubMed |
| 18 | 18081792 | Low response rate of second-line chemotherapy for recurrent or refractory clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study. | Int J Gynecol Cancer | 2008 | https://conductscience.org/library/papers/18081792 | PubMed |
| 19 | 32581055 | IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma. | J Immunother Cancer | 2020 | https://conductscience.org/library/papers/32581055 | PubMed |
| 20 | 31924330 | High homogeneity of MMR deficiency in ovarian cancer. | Gynecol Oncol | 2020 | https://conductscience.org/library/papers/31924330 | PubMed |
Cited by5
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42984928 | Immunotherapy in Advanced Epithelial Ovarian Cancer: Successes and Frustrations. | Oncol Res | 2026 | https://conductscience.org/library/papers/42984928 | PubMed |
| 42891872 | Histotype and molecular subtype integration in epithelial ovarian cancer: implications for targeted treatment. | Cancer Metastasis Rev | 2026 | https://conductscience.org/library/papers/42891872 | PubMed |
| 41888752 | Twenty-four months progression-free survival (ongoing) for treatment of recurrent ovarian clear cell carcinoma with surufatinib in combination with toripalimab: a case report. | BMC Womens Health | 2026 | https://conductscience.org/library/papers/41888752 | PubMed |
| 41697393 | AI-based quantification of tumor-infiltrating lymphocytes with integrative transcriptomics in ovarian clear cell carcinoma: JGOG3025-TR1/A1 study. | Cancer Immunol Immunother | 2026 | https://conductscience.org/library/papers/41697393 | PubMed |
| 41020848 | Tumor Immune Microenvironment and Checkpoint Inhibition in Clear Cell Ovarian Carcinoma: Bridging Tumor Biology and Clinical Application in Immunotherapy. | Curr Issues Mol Biol | 2025 | https://conductscience.org/library/papers/41020848 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD274 | 29126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| PIK3CA | 5290 | PubTator's text mining | https://conductscience.org/library/genes/5290 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40705396
GET https://conductscience.org/api/papers/v1/40705396/references?page=2